Large Molecule vs Small Molecule Drug Product Outsourcing

In Q42020, ISR surveyed 110 sponsors who outsource biologic drug product manufacturing to gain insight into how drug product outsourcing is distributed at their organizations. 37% of respondents stated a larger proportion of biologic drug product manufacturing is outsourced compared to small molecule drug product. 39% said drug product manufacturing is outsourced at the same rate across molecule types. To learn more, follow the link to the Biologic Drug Product Contract Manufacturer Quality Benchmarking report preview.